0.3502

1.07% -0.0038

After Hours: .35 -0.0002 -0.06%

Iterum Therapeutics Plc (ITRM)

Overview News Price History Financials Why ITRM Down? Discussions Forecast Stock Split

Iterum Therapeutics Plc stock is traded at $0.3502, with a volume of 648.74K. It is down -1.07% in the last 24 hours and down -25.81% over the past month. Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Previous Close:

$0.354

Open:

$0.365

24h Volume:

648.74K

Relative Volume:

0.64

Market Cap:

$18.66M

Revenue:

Net Income/Loss:

$-24.08M

P/E Ratio:

-0.4085

EPS:

-0.8572

Net Cash Flow:

$-14.75M

1W Performance:

+21.56%

1M Performance:

-25.81%

6M Performance:

-63.67%

1Y Performance:

-82.31%

1-Day Range:

$0.34

$0.3731

1-Week Range:

$0.26

$0.3972

52-Week Range:

$0.26

$2.03

Iterum Therapeutics Plc Stock (ITRM) Company Profile

Name

Iterum Therapeutics Plc

Sector

Healthcare (1115)

Industry

Biotechnology (624)

Phone

(872) 225-6077

Address

3 DUBLIN LANDINGS, DUBLIN 1

Employee

Twitter

Next Earnings Date

2025-02-07

Latest SEC Filings

ITRM's Discussions on Twitter

Compare ITRM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ITRM Iterum Therapeutics Plc	0.3502	18.87M	0	-24.08M	-14.75M	-0.8572
VRTX Vertex Pharmaceuticals Inc	468.38	113.87B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	776.54	80.22B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	406.40	52.56B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	803.74	49.31B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	175.07	37.37B	447.02M	-1.18B	-906.14M	-6.1812

Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-28-21	Upgrade	Gabelli & Co	Sell → Hold
Mar-15-21	Upgrade	H.C. Wainwright	Neutral → Buy
Jun-02-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jan-21-20	Downgrade	Gabelli & Co	Buy → Sell
Dec-11-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jun-21-19	Initiated	H.C. Wainwright	Buy

View All

Iterum Therapeutics Plc Stock (ITRM) Latest News

04:36 AM

Will Iterum Therapeutics plc stock benefit from green energy trends2026 world cup usa national team qualification star players possession football odds analysis analysis - Улправда

04:36 AM

Dec 23, 2025

Iterum Therapeutics expands market access for ORLYNVAH antibiotic - Investing.com

Dec 23, 2025

Iterum Therapeutics provides business update - marketscreener.com

Dec 23, 2025

Iterum Therapeutics Provides Business Update - The Manila Times

Dec 23, 2025

New antibiotic ORLYNVAH could reach 34M+ people pending FDA feedback - Stock Titan

Dec 23, 2025

Dec 19, 2025

Why Iterum Therapeutics plc stock remains a top recommendationTrade Performance Summary & Weekly Return Optimization Alerts - Улправда

Dec 19, 2025

Analyzing Iterum Therapeutics (NASDAQ:ITRM) & Savara (NASDAQ:SVRA) - Defense World

Dec 19, 2025

Dec 18, 2025

Why hedge funds are buying Iterum Therapeutics plc stockWeekly Trade Analysis & Capital Efficient Trade Techniques - Улправда

Dec 18, 2025

Dec 17, 2025

Iterum Therapeutics secures major PBM agreement for antibiotic By Investing.com - Investing.com Nigeria

Dec 17, 2025

Iterum Therapeutics (ITRM) Secures Key PBM Agreement and Expands Patent Portfolio - GuruFocus

Dec 17, 2025

Iterum Therapeutics secures major PBM agreement for antibiotic - Investing.com

Dec 17, 2025

New PBM deal could open ORLYNVAH access to 40M more people in 2026 - Stock Titan

Dec 17, 2025

Dec 14, 2025

Iterum Therapeutics faces Nasdaq listing compliance challenge - MSN

Dec 14, 2025

Dec 13, 2025

Iterum Therapeutics Faces Nasdaq Listing Compliance Challenge - The Globe and Mail

Dec 13, 2025

Iterum Therapeutics receives Nasdaq notice on listing compliance By Investing.com - Investing.com Australia

Dec 13, 2025

Dec 12, 2025

Iterum Therapeutics plc Stock Analysis and ForecastEarnings Forecast Updates & Fast Profit Stock Ideas - earlytimes.in

Dec 12, 2025

Iterum Therapeutics receives Nasdaq notice on listing compliance - Investing.com

Dec 12, 2025

Iterum Therapeutics (NASDAQ: ITRM) discloses Nasdaq delisting risk on value, price - Stock Titan

Dec 12, 2025

Dec 09, 2025